We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

33 hedge funds and large institutions have $9.1M invested in Xilio Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

10% more funds holding

Funds holding: 30 → 33 (+3)

0.18% more ownership

Funds ownership: 4.11% → 4.29% (+0.18%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

73% less capital invested

Capital invested by funds: $33.5M → $9.1M (-$24.4M)

Holders
33
Holders Change
+3
Holders Change %
+10%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
6
Increased
8
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$322K
2
Renaissance Technologies
Renaissance Technologies
New York
+$267K
3
ACH
ArrowMark Colorado Holdings
Colorado
+$118K
4
Citadel Advisors
Citadel Advisors
Florida
+$72.6K
5
BCM
Bridgeway Capital Management
Texas
+$63.6K

Top Sellers

1
HMC
Harvard Management Company
Massachusetts
-$878K
2
OCA
Octagon Capital Advisors
New York
-$754K
3
SCM
Soleus Capital Management
Connecticut
-$479K
4
Bank of America
Bank of America
North Carolina
-$320K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$55.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$1.54M – – –
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$1.52M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$1.05M – – –
OCA
4
Octagon Capital Advisors
New York
$982K -$754K -38,107 -23%
TPC
5
Takeda Pharmaceutical Company
Japan
$811K +$2.08M +105,366 New
RVM
6
RiverVest Venture Management
Missouri
$793K – – –
RSCM
7
Rock Springs Capital Management
Maryland
$792K – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$496K +$17.2K +870 +1%
AG
9
Artal Group
Luxembourg
$248K – – –
Morgan Stanley
10
Morgan Stanley
New York
$140K +$322K +16,305 +869%
TOCUITCONY
11
Trustees of Columbia University in the City of New York
New York
$137K – – –
Fidelity International
12
Fidelity International
Bermuda
$120K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$115K +$267K +13,500 +913%
BCM
14
Bridgeway Capital Management
Texas
$85.5K +$63.6K +3,214 +41%
LCM
15
Laurion Capital Management
New York
$64.3K -$31.7K -1,601 -16%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$46.7K – – –
ACH
17
ArrowMark Colorado Holdings
Colorado
$45.9K +$118K +5,955 New
Citadel Advisors
18
Citadel Advisors
Florida
$28.3K +$72.6K +3,673 New
BlackRock
19
BlackRock
New York
$25.8K -$751 -38 -1%
Millennium Management
20
Millennium Management
New York
$16.7K +$42.9K +2,168 New
Northern Trust
21
Northern Trust
Illinois
$9.79K – – –
State Street
22
State Street
Massachusetts
$8.63K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$7.69K +$14.3K +721 +260%
Charles Schwab
24
Charles Schwab
California
$6.56K – – –
VF
25
Virtu Financial
New York
$6K +$15.2K +769 New
1
2

XLO Hedge Fund Activity: Q4 2023 in Review

33 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2023, worth a combined $9.1M — down 73% from $33.5M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XLO positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $322K. The largest seller was Harvard Management Company, exiting entirely with an estimated $878K sold.

  • 33 institutional investors held Xilio Therapeutics (XLO) as of Q4 2023, up from 30 in Q3 2023.
  • Funds reported $9.1M of Xilio Therapeutics stock for Q4 2023, down 73% quarter-over-quarter.
  • 6 funds opened new Xilio Therapeutics positions in Q4 2023 and 3 closed out, a net change of +3 holders.
  • The largest Xilio Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $322K added.
  • The largest Xilio Therapeutics seller in Q4 2023 was Harvard Management Company, an estimated $878K sold.

Based on aggregated 13F filings for Q4 2023.